Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03225443
Other study ID # Xiaoqing Guo
Secondary ID
Status Not yet recruiting
Phase N/A
First received July 19, 2017
Last updated July 19, 2017
Start date September 30, 2017
Est. completion date September 30, 2020

Study information

Verified date July 2017
Source Shanghai First Maternity and Infant Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Locally advanced cervical cancer (LACC) refers to the clinically cervical visible lesion with a diameter of > 4 cm, which has been considered as a high risk of early cervical cancer for a long time. Because of local bulk lesion of LACC, the risk of radical hysterectomy is pretty high and the radical effect commonly does not meet the satisfactory. Therefore, 1-3 course of neoadjuvant chemotherapy (NACT) were carried out before operation. However, nearly 20% of patients are not sensitive to NACT. Therefore NACT did not bring any benefits to radical surgery even to some extent delayed the treatment.

Traditional radiotherapy is also commonly used in the treatment of LACC, however ovarian function would be permanently destroyed especially for young patients, additionally radioactive complications to adjacent organs of cervical such as vagina, bladder and rectal also commonly happened, moreover sexual dysfunction after radiotherapy significantly affect the life quality of young patients.

Particle radiotherapy developed recently, has the advantages of short course of treatment and mild side effects, due to its special working mechanism, Bragg effect. So the amount of radiation in the tumor tissue is very extremely high, and in the adjacent tissue is quiet low, therefore the organs at risk were protected by avoiding unnecessary damage.

Based on these, we proposed the application of particle radiotherapy in LACC pre-operation, and comprehensively evaluated recent curative effect, complications and long-term follow-up between particle radiotherapy and NACT. Furthermore, the clinical significance and long-term application prospects about particle therapy were objectively assessed.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date September 30, 2020
Est. primary completion date September 30, 2020
Accepts healthy volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

1. Pathological diagnosis: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma

2. The pathological staging: IB2,IIA2

Exclusion Criteria:

Underwent surgery or radiation and chemotherapy

Study Design


Locations

Country Name City State
China Shanghai First Maternity and Infant Hospital Shanghai

Sponsors (3)

Lead Sponsor Collaborator
Shanghai First Maternity and Infant Hospital RenJi Hospital, Shanghai Proton and Heavy Ion Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The recurrence rate 3 years after treatment
Secondary The transfer rate 3 years after treatment
Secondary mortality 3 years after treatment
See also
  Status Clinical Trial Phase
Recruiting NCT01373723 - Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer N/A
Terminated NCT01234480 - Intended Use Study of the BD SurePath Plus™ Pap
Completed NCT02808832 - An HPV Vaccine Provider Intervention in Safety Net Clinics N/A
Terminated NCT01194609 - A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer Phase 1/Phase 2
Terminated NCT01075412 - FLT PET Imaging for Cervical Cancer Phase 2
Completed NCT01014026 - Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Phase 3
Completed NCT02865889 - Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications N/A
Completed NCT00377845 - Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear. Phase 0
Recruiting NCT05531981 - Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
Recruiting NCT05393440 - First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer Phase 1
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT02866006 - Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer Phase 1/Phase 2
Completed NCT03270995 - Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study N/A
Completed NCT02320578 - 2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Not yet recruiting NCT05065853 - Urinary and Vaginal HPV Testing in Cervical Cancer Screening
Completed NCT01231945 - Low-Cost Molecular Cervical Cancer Screening Study N/A
Completed NCT01717391 - [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Phase 2
Active, not recruiting NCT04947605 - Epidemiological Landscape of Cervical Cancer in Latin America
Recruiting NCT06124040 - Sexual Function, Coping and Dyadic Coping in Patients With Cervical Cancer